MolMed

MolMed S.p.A. is an Italy-based medical biotechnology company dedicated to the research, development, and clinical validation of innovative cancer therapies. Its pipeline features several antitumor therapeutics currently in clinical and preclinical phases. Zalmoxis® (TK) is a cell-based therapy designed to facilitate bone marrow transplants from partially compatible donors without requiring post-transplant immune suppression; it is currently in Phase III trials for high-risk acute leukemia and is undergoing evaluation by the European Medicines Agency for Conditional Marketing Authorization. Another key product, NGR-hTNF, is a novel treatment for solid tumors that targets the blood vessels supplying the tumor mass, and it is being investigated in an extensive clinical program. Additionally, MolMed is developing CAR-CD44v6, an immuno-gene therapy project aimed at treating various hematological malignancies and epithelial tumors, which is in preclinical development. The company also collaborates with third parties on cell and gene therapy projects, providing expertise and resources for trials ranging from preclinical stages to Phase III.